In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
about
Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implicationsAntifungal Activity of the Biphosphinic Cyclopalladate C7a against Candida albicans Yeast Forms In Vitro and In Vivo.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Micafungin in the treatment of invasive candidiasis and invasive aspergillosisPharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model.Limited-sampling strategies for anidulafungin in critically ill patients.Efficacy of combination therapy of triazole and echinocandin in treatment of invasive aspergillosis: a systematic review of animal and human studiesPharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsAntifungal pharmacokinetics and pharmacodynamicsIntermittent Dosing of Micafungin Is Effective for Treatment of Experimental Disseminated Candidiasis in Persistently Neutropenic Rabbits.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis.Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafunginIsavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.Anidulafungin treatment of candidal central nervous system infection in a murine modelEvaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility.Antifungal therapeutic drug monitoring: established and emerging indications.Anidulafungin: a novel echinocandin for candida infections.Pharmacology and antifungal properties of anidulafungin, a new echinocandin.Paradoxical echinocandin activity: a limited in vitro phenomenon?Low but sufficient anidulafungin exposure in critically ill patients.Current perspectives on echinocandin class drugs.Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults.A clinical review of echinocandins in pediatric patients.Echinocandin pharmacodynamics: review and clinical implications.Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Anidulafungin: is it a promising option in the treatment of pediatric invasive fungal infections?Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients.Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters.Echinocandins: The Expanding Antifungal Armamentarium.Echinocandins in antifungal pharmacotherapy.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsDose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.Efficacy of Extended-Interval Dosing of Micafungin Evaluated Using a Pharmacokinetic/Pharmacodynamic Study with Humanized Doses in Mice.
P2860
Q27025299-55472F59-3731-41CD-AC47-FDC0A8050521Q33628033-C9F076F8-CE2E-4842-B7D0-096DFE80E8A6Q33876423-056528BB-20F0-4E36-85CE-3F5B37D9AB7AQ34186442-3AF04EF2-E9B2-4EAE-99D0-2C424F95853FQ34933267-E2989DFE-2784-4FC5-AC87-45786FD5B911Q35026516-AEE77E32-DA2C-4DA7-BE81-9932EFA0D190Q35105763-5F405A93-1F4D-4E1F-9A2A-83B553133F18Q35105939-69CC2D75-16ED-4865-A34E-AE4D9F85E2F8Q35113648-60C438E4-3867-4FAC-B7FE-A88E722BE093Q35270758-F634796B-306B-44E4-A607-E583E370DC8EQ35663841-9BAFDA5C-80C9-42A7-88F0-6BF433ABD3C5Q36276191-8F6D7DF1-FD73-4220-87B4-5C27BD798AAEQ36364100-B0C5E3DD-4D6C-4EB8-9666-ACECB0334A5FQ36505401-5AF80B5E-ED45-459D-9813-3476E63FFC38Q36845482-7D969E7E-5A1A-477B-996D-3F3B611D5C3EQ36932989-F632890F-90D3-41D0-A09B-CA695BAC87A4Q36949553-40871583-40F5-4B68-9EF1-29F1F41275B8Q37190801-7E272644-BE00-4E48-9D7D-8EC40A97BF5FQ37263435-2541C62E-9195-44DC-8775-8D85051DE0E2Q37274734-F17A2E6E-9922-4AFE-AD7A-3478B7DF0985Q37291442-034D5FE5-0D8F-496C-842E-568C139F1472Q37310029-488FCC79-1F11-4236-9CA9-88710B0C3728Q37345790-EAD5D38B-4BF1-4FB0-85E5-BAC86BA5ED55Q37359613-4A8D167F-A8E9-48A9-BDFE-EABEE8169ED5Q37405284-2D96E930-1D28-45AF-9EFF-1A8D408BF96FQ37544395-227CFCAA-D410-48E7-916D-FD129CE3E4F7Q37554055-4BB08744-9C00-4E8E-A5C2-9EABB28A4ACCQ37612980-ED94975E-4A27-4BBC-9E93-2E7F88C28241Q37653647-1F33D532-3585-4F9A-A344-25C31C2F4FD0Q37718385-346E4F60-A62A-4008-9B52-175BD3ECC4CAQ37785979-0EF78B75-21C5-4ACF-AD7B-8382CCFAA523Q37854724-BD8B257E-6F8E-4930-A067-B65E2C342020Q38193337-8DFC3FD7-4852-45A5-AF72-0B1E5FDBC057Q38419657-6A9AC82D-CB30-4813-9D41-EC7C4F6FBB96Q38605120-4D2E548A-BC8E-4A89-934F-08DA82A2640AQ38633102-65C74447-C98E-4498-8ABF-FD551F05055FQ39458862-BBBF2295-9969-42E4-BBD7-AF646A78CADCQ39701953-1E0CB44E-1F9F-443A-B2ED-CD978F801828Q40587101-CC98FF92-EF93-4389-968E-FD9B01E92E85Q40916536-98A1F68F-380B-4546-81F6-7BD55B81E3EB
P2860
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@ast
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@en
type
label
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@ast
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@en
prefLabel
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@ast
In vivo pharmacodynamic charac ...... enic murine candidiasis model.
@en
P2093
P2860
P356
P1476
In vivo pharmacodynamic charac ...... penic murine candidiasis model
@en
P2093
P2860
P304
P356
10.1128/AAC.01061-07
P407
P577
2007-12-10T00:00:00Z